Elsevier

Neuropeptides

Volume 32, Issue 1, February 1998, Pages 1-49
Neuropeptides

The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles

https://doi.org/10.1016/S0143-4179(98)90015-4Get rights and content

Abstract

The tachykinin NK1 receptor is widely distributed in both the central and peripheral nervous system. In the CNS, NK1 receptors have been implicated in various behavioural responses and in regulating neuronal survival and degeneration. Moreover, central NK1 receptors regulate cardiovascular and respiratory function and are involved in activating the emetic reflex.

At the spinal cord level, NK1 receptors are activated during the synaptic transmission, especially in response to noxious stimuli applied at the receptive field of primary afferent neurons. Both neurophysiological and behavioural evidences support a role of spinal NK1 receptors in pain transmission. Spinal NK1 receptors also modulate autonomic reflexes, including the micturition reflex.

In the peripheral nervous system, tachykinin NK1 receptors are widely expressed in the respiratory, genitourinary and gastrointestinal tracts and are also expressed by several types of inflammatory and immune cells. In the cardiovascular system, NK1 receptors mediate endothelium-dependent vasodilatation and plasma protein extravasation. At respiratory level, NK1 receptors mediate neurogenic inflammation which is especially evident upon exposure of the airways to irritants. In the carotid body, NK1 receptors mediate the ventilatory response to hypoxia. In the gastrointestinal system, NK1 receptors mediate smooth muscle contraction, regulate water and ion secretion and mediate neuro-neuronal communication. In the genitourinary tract, NK1 receptors are widely distributed in the renal pelvis, ureter, urinary bladder and urethra and mediate smooth muscle contraction and inflammation in response to noxious stimuli.

Based on the knowldege of distribution and pathophysiological roles of NK1 receptors, it has been anticipated that NK1 receptor antagonists may have several therapeutic applications at central and peripheral level. At central level, it is speculated that NK1 receptor antagonists could be used to produce analgesia, as antiemetics and for treatment of certain forms of urinary incontinence due to detrusor hyperreflexia. In the peripheral nervous system, tachykinin NK1 receptor antagonists could be used in several inflammatory diseases including arthritis, inflammatory bowel diseases and cystitis.

Several potent tachykinin NK1 receptor antagonists are now under evaluation in the clinical setting, and more information on their usefulness in treatment of human diseases will be available in the next few years.

References (644)

  • M Taoka et al.

    Increased level of NK1 tachykinin receptor gene expression during early postnatal development of rat brain

    Neuroscience

    (1996)
  • M Herkenham

    Mismatches between neurotransmitter and receptor localizations in brain: observations and implications

    Neuroscience

    (1987)
  • PJ Elliott et al.

    Modulation of the rat mesolimbic dopamine pathway by neurokinins

    Behav Brain Res

    (1992)
  • LJ Bristow et al.

    Chromodachryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils

    Eur J Pharmacol

    (1994)
  • AJ Stoessl et al.

    Pharmacological characterization of grooming induced by a selective NK1 tachykinin receptor agonist

    Brain Res

    (1995)
  • Y Shirayama et al.

    Reduction of substance P after chronic antidepressant treatment in the striatum, substantia nigra and amygdala of the rat

    Brain Res

    (1996)
  • U Liminga et al.

    Intranigral stimulation of oral movements by [Pro9]substance P a NK1 receptor agonist, is enhanced in chronically neuroleptic-treated rats

    Behav Brain Research

    (1993)
  • R Maldonado et al.

    RP 67,580, a selective antagonist of NK1 receptors modifies some of the naloxone precipitated morphine withdrawal signs in rats

    Neurosci Letters

    (1993)
  • W Krase et al.

    Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats

    Behav Brain Res

    (1994)
  • MB Shaikh et al.

    Evidence that SP is utilized in medial amygdaloid facilitation of defensive rage behaviour in the cat

    Brain Res

    (1993)
  • RM Teixeira et al.

    Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behaviour in mice

    Eur J Pharmacol

    (1996)
  • G Zernig et al.

    The substance P (NK1) receptor antagonist (±)CP 96345 causes sedation and motor impairment of Swiss albino mice in the black-and-white box behavioral paradigm

    Neurosci Letters

    (1992)
  • Y Iwasaki et al.

    Trophic effects of various neuropeptides on the cultured ventral spinal cord of rat embryo

    Neurosci Letters

    (1989)
  • N Calvo et al.

    Tachykinins protect chlinergic neurons from quinolinic acid excitotoxicity in striatal cultures

    Brain Res

    (1996)
  • M Taoka et al.

    Increased level of NK1 tachykinin receptor gene expression during early postnatal development of rat brain

    Neuroscience

    (1996)
  • Y Shimohigashi et al.

    Receptor-mediated specific biological activity of a β-amyloid protein fragment for NK1 substance P receptors

    Bochem Biophys Res Comm

    (1993)
  • M Mitsuhashi et al.

    Amyloid β protein substituent peptides do not interact with the SP receptor expressed in cultured cells

    Mol Brain Res

    (1991)
  • P Rovero et al.

    Interaction of amyloid β protein (25–35) with tachykinin receptors

    Neuropeptides

    (1992)
  • MS Shearman

    Cellular MTT reduction distinguishes the mechanism of action of β-amyloid from that of tachykinin receptor peptides

    Neuropeptides

    (1996)
  • FC Martin et al.

    Substance P stimulates IL-1 production by astrocytes via intracellular calcium

    Brain Res

    (1992)
  • SK Kostyk et al.

    Substance P immunoreactive astrocytes are present in multiple sclerosis plaques

    Brain Res

    (1989)
  • CM Lee et al.

    Functional Substance P receptors on a human astrocytoma cell line (U 373 MG)

    Brain Res

    (1989)
  • C Palma et al.

    Different susceptibility to NK1 receptor antagonists of substance P and septide-induced IL-6 release from U373 MG human astrocytoma cell line

    Neurosci Letters

    (1994)
  • A Saigo et al.

    Role of NK1 receptor in central cardiovascular regulation in rats: studies on a novel nonpeptide antagonist, CP 96345, of substance P NK1 receptor

    Regul Peptides

    (1993)
  • N Lindefors et al.

    In vivo release of substance P in nucleus tractus solitarius increases during hypoxia

    Neurosci Letters

    (1986)
  • F Martini et al.

    Effect of substance P on cardiovascular regulation in the rabbit

    J Autonom Nervous System

    (1995)
  • R Monteau et al.

    Tachykinins and central respiratory activity: an in vitro study on the newborn rat

    Eur J Pharmacol

    (1996)
  • M Yamazoe et al.

    Distribution of six neuropeptides in the nucleus tractus solitarii of the rat: an immunohistochemical analysis

    Neuroscience

    (1984)
  • CJ Helke et al.

    Autoradiographic localization of substance P receptors in rat medulla: effect of vagotomy and nodose ganglionectomy

    Neuroscience

    (1984)
  • LA Ladic et al.

    Association of substance P and its receptor with efferent neurons projecting to the greater curvature of the rat stomach

    J Autonom Nervous System

    (1996)
  • RA Gillis et al.

    Evidence that SP is a neurotransmitter of baro- and chemoreceptor afferents in nucleus tractus solitarius

    Brain Res

    (1980)
  • L Segu et al.

    Up-regulation of SP binding sites in the vagus nerve projection area of the cat brainstem after nodosectomy

  • F Martini-Luccarini et al.

    Effects of tachykinins on identified dorsal vagal neurons: an electrophysiological study in vitro

    Neuroscience

    (1996)
  • C Bountra et al.

    Antiemetic profile of a nonpeptide neurokinin NK1 receptor antagonist, CP 99994 in ferrets

    Eur J Pharmacol

    (1993)
  • FD Tattersall et al.

    The tachykinin NK1 receptor antagonist, CP 99994 attenuates cisplatin-induced emesis in the ferret

    Eur J Pharmacol

    (1993)
  • JL Henry

    Discussion of nomenclature for tachykinins and tachykinin receptors

  • Y Yokota et al.

    Molecular characterization of a functional cDNA for rat receptor

    J Biol Chem

    (1989)
  • AD Hershey et al.

    Molecular characterization of a functional cDNA encoding the rat substance P receptor

    Science

    (1990)
  • M Yanagisawa et al.

    Pharmacological profile of a tachykinin antagonist, spantide, as examined on rat spinal cord motorneurones

    Br J Pharmacol

    (1990)
  • JM Hall et al.

    Tachykinin NK1 receptor ligands show two distinct pharmacological profiles in rabbit iris sphincter

    Br J Pharmacol

    (1994)
  • Cited by (270)

    View all citing articles on Scopus
    View full text